Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Investing cash flow turns negative

Q4 FY2025 investing cash flow was -$9.83M, compared with $3.36M a year earlier. Trailing-twelve-month investing cash flow was -$1.77M.

Context

  • Investing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near -$9.83M or moves back toward the trailing-twelve-month quarterly average of -$442.68K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$9.83M-357.6% QoQ
Last fiscal yearDec 2025
-$1.32M-114.6% YoY
LTMDec 2025
-$1.77M-119.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-392.7%——
1 year-114.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(1.32M) USD
Year-over-year change
-114.6%

Investing Cash Flow vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's LTM Dec 2025 investing cash flow of $1.77M is the largest of the 2 companies compared; the peer median is $113.15K.
  • Its year-over-year change of -119.5% is the lowest of 2, against a peer median of +264.4%.
ENLV Competitors Peer median
Investing Cash Flow for ENLV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$1.77M -119.5%——
NRXSNeurAxis, Inc.LTM Mar 2026$113.15K +264.4%+28.9%2.6%
Peer median (excluding ENLV) $113.15K+264.4%+28.9%2.6%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.47M)(31.06M)(29.07M)(15.01M)1.24B
Depreciation & Amortization546K777K835K545K332K
Deferred Income Tax(5.59M)000382.65M
Stock-Based Compensation2.91M2.71M1.95M2.07M1.78M
Change in Working Capital(1.36M)804K(1.82M)(1.22M)815K
Accounts Receivables(1.25M)278K608K433K(3.05M)
Inventory1.25M(278K)000
Accounts Payables442K1.17M(1.12M)(16K)3M
Other Working Capital(1.8M)(364K)(1.31M)(1.64M)869K
Other Non-Cash Items413K2.81M4.58M614K(1.63B)
Operating Cash Flow(17.54M)(23.95M)(23.52M)(13.01M)(10.42M)
Capital Expenditures(1.63M)(8.12M)(236K)(103K)(68K)
Acquisitions (Net)(20.03M)(9.71M)001.38M
Purchases of Investments(104.42M)(1.61M)(26.17M)(32.37M)(24.5M)
Sales of Investments67.63M72.25M301K39.24M41.37M
Other Investing Activities20.03M9.71M133K2.29M0
Investing Cash Flow(38.41M)62.52M(25.97M)9.06M(1.32M)
Debt Repayment00000
Common Stock Issued53.17M150K360K6.45M10.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.81M002K0
Financing Cash Flow60.98M150K360K6.45M10.38M
Effect of Forex Changes(408K)(91K)00(49K)
Net Change in Cash4.62M38.72M(49.13M)2.51M(1.41M)
Free Cash Flow(19.17M)(32.08M)(23.76M)(13.11M)(10.48M)

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.